LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
10.18632/oncotarget.25835
Saved in:
Main Authors: | , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/178073 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
id |
sg-nus-scholar.10635-178073 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-1780732024-04-18T03:02:55Z LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) Hee, Y.T Yan, J Nizetic, D Chng, W.-J CANCER SCIENCE INSTITUTE OF SINGAPORE MEDICINE cyclin dependent kinase 4 cyclin dependent kinase 6 Janus kinase 1 Janus kinase 2 ribociclib ruxolitinib STAT protein Article cancer combination chemotherapy cancer inhibition cell cycle progression cell viability controlled study drug efficacy drug potentiation drug targeting enzyme inhibition IC50 lymphoma cell line monotherapy NK T cell lymphoma 10.18632/oncotarget.25835 Oncotarget 9 61 31832-31841 2020-10-20T05:00:52Z 2020-10-20T05:00:52Z 2018 Article Hee, Y.T, Yan, J, Nizetic, D, Chng, W.-J (2018). LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). Oncotarget 9 (61) : 31832-31841. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.25835 19492553 https://scholarbank.nus.edu.sg/handle/10635/178073 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031 |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
topic |
cyclin dependent kinase 4 cyclin dependent kinase 6 Janus kinase 1 Janus kinase 2 ribociclib ruxolitinib STAT protein Article cancer combination chemotherapy cancer inhibition cell cycle progression cell viability controlled study drug efficacy drug potentiation drug targeting enzyme inhibition IC50 lymphoma cell line monotherapy NK T cell lymphoma |
spellingShingle |
cyclin dependent kinase 4 cyclin dependent kinase 6 Janus kinase 1 Janus kinase 2 ribociclib ruxolitinib STAT protein Article cancer combination chemotherapy cancer inhibition cell cycle progression cell viability controlled study drug efficacy drug potentiation drug targeting enzyme inhibition IC50 lymphoma cell line monotherapy NK T cell lymphoma Hee, Y.T Yan, J Nizetic, D Chng, W.-J LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
description |
10.18632/oncotarget.25835 |
author2 |
CANCER SCIENCE INSTITUTE OF SINGAPORE |
author_facet |
CANCER SCIENCE INSTITUTE OF SINGAPORE Hee, Y.T Yan, J Nizetic, D Chng, W.-J |
format |
Article |
author |
Hee, Y.T Yan, J Nizetic, D Chng, W.-J |
author_sort |
Hee, Y.T |
title |
LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
title_short |
LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
title_full |
LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
title_fullStr |
LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
title_full_unstemmed |
LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
title_sort |
lee011 and ruxolitinib: a synergistic drug combination for natural killer/t-cell lymphoma (nktcl) |
publishDate |
2020 |
url |
https://scholarbank.nus.edu.sg/handle/10635/178073 |
_version_ |
1800914474098491392 |